Development of using 3D scanning, 3D printing and computer modelling techniques to improve inhalation systems

AIT 2024 -- Labcorp has many years of experience performing nonclinical inhalation safety studies, and animal welfare is always of the utmost importance. There is a drive to improve animal welfare and study integrity, which aids study interpretation. At Labcorp, some of the developmental techniques that we have used over the years are 3D scanning, 3D printing and Computational Fluid Dynamic (CFD) modelling. These development techniques have allowed us to improve large animal facemask and rodent restraint tube design and help us to better understand animal inhalation exposure systems.

A new 30-color spectral flow cytometry panel for T cell therapy phenotypic characterization

CAR-TCR Summit 2024 -- Spectral flow cytometers have immunophenotypic analysis with panels exceeding 30 colors to provide deep insights into the immune response. Labcorp has developed a 30-color immunophenotyping panel using the Cytek Aurora Spectral Flow Cytometer. The panel backbone includes one viability dye and ten lineage markers to profile T cell, NK and B cell subsets. Nineteen additional functional markers enable the characterization of activation, exhaustion, cytotoxicity and proliferation in each subset, plus memory T cell subset delineation. Explore the data in this poster that demonstrates how spectral flow cytometry can be applied to assess T cell therapies in studies that span in vitro assessments, preclinical tumor-bearing mouse models, through clinical trials.

Labcorp Expands Molecular Bioanalytical Laboratory in Greenfield, Indiana

BURLINGTON, N.C., Sept. 18, 2024 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its molecular bioanalytical laboratory in Greenfield, Indiana. 

ATN Profile: For and beyond Alzheimer’s disease

Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60%-70% of dementia cases.1 Blood-based biomarkers (BBMs) specific to AD pathology, such as beta-amyloid 42/40 and pTau217, are now available to clinicians. But this still leaves up to 40% of patients with clinical signs of mild cognitive impairment (MCI) or possible dementia without answers.

Blue Cross and Blue Shield of Alabama Announces Relationship with Labcorp to Provide Members Best Overall Value for Outpatient Lab-Related Services

BIRMINGHAM, AL, Sept. 17, 2024 – Blue Cross and Blue Shield of Alabama’s mission is to provide our members access to high quality, affordable care, delivered by the most cost-effective healthcare providers.

The importance of the cynomolgus macaque’s origin in drug safety assessment

Cynomolgus macaques are the most commonly used non-human primate species for drug safety assessment. However, recent supply shortages  have brought increased attention to the genetic differences between cynomolgus macaques of varying geographic origins. It is important to examine the relevance of geographic origin for cynomolgus macaques used in regulatory toxicology studies.

Key learnings from ECHA's review of the EOGRTS (OECD Test Guideline 443)

The extended one-generation reproductive toxicity study (EOGRTS) per OECD Test Guideline 443 is a crucial test for evaluating potential reproductive and developmental effects of chemicals. Recently, the European Chemicals Agency (ECHA) conducted an extensive review of EOGRTS  studies to assess the effectiveness of this test guideline and provide recommendations for improvement. This blog post summarizes  key learnings from ECHA's review and the impacts on current and future EOGRTS study design.

Cinven to sell minority stake in SYNLAB to strategic investor Labcorp

International private equity firm, Cinven, has reached an agreement to sell an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive laboratory services

LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034

BURLINGTON, N.C. , Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) ( Labcorp ) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering).